Dysport in the Treatment of Glabellar Lines in Chinese Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

520

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

September 6, 2017

Conditions
Glabellar Lines
Interventions
BIOLOGICAL

Botulinum toxin type A

BIOLOGICAL

Botulinum toxin type A

DRUG

Placebo

50 Units

DRUG

Placebo

20 Units

Trial Locations (10)

100034

Peking University First Hospital, Beijing

100142

Air Force General Hospital, PLA, Beijing

100730

Peking Union Medical College Hospital, Beijing

100853

Chinese PLA General Hospital, Beijing

210042

Dermatology Hospital of the Chinese Academy of Medical Sciences, Nanjing

300052

Tianjin Medical University General Hospital, Tianjing

410013

The Third Xiangya Hospital of Central South University, Changsha

430022

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

510630

The Third Affiliated Hospital of Sun Yat-sen University, Guanzhou

610041

West China Hospital, Sichuan University, Chengdu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY